RDY
DR REDDYS LABORATORIES LTD
Next earnings Jul 21, 2026 · consensus $9.79 EPS, $81.0B rev
$15.38
▲ +0.85%$15.38▲ +1.62%
over 1Y
L $12.46EODHDH $15.49
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.9%
1W+10.6%
1M+13.3%
3M+14.1%
YTD+11.0%
1Y+1.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 44 analysts
Hold
Indian pharma ADR with no SEC XBRL fundamentals beyond a share count — nothing to underwrite at $13.29.
Dr. Reddy's Laboratories is an Indian generic and specialty pharmaceutical company that files with the SEC as a foreign private issuer on Form 6-K. The structured data available here is essentially empty — only a share count of 835M (FY2026) — with no revenue, earnings, margins, cash flow, or balance-sheet figures. Without any income-statement or balance-sheet information, there is no basis to evaluate the business's growth, profitability, leverage, or whether $13.29 is cheap or expensive.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$12.8B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-252026-06-26open ↗6-KPeriod ending 2026-06-222026-06-22open ↗6-KPeriod ending 2026-06-202026-06-22open ↗6-KPeriod ending 2026-06-192026-06-22open ↗6-KPeriod ending 2026-06-132026-06-15open ↗6-KPeriod ending 2026-06-102026-06-10open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-06-032026-06-03open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-302026-06-01open ↗20-FPeriod ending 2026-03-312026-05-29open ↗6-KPeriod ending 2026-05-282026-05-28open ↗
Frequently asked
- Is DR REDDYS LABORATORIES LTD (RDY) a buy?
- RDY currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Indian pharma ADR with no SEC XBRL fundamentals beyond a share count — nothing to underwrite at $13.29.
Sources: SEC EDGAR (CIK 0001135951, latest 6-K filed 2026-06-26) · EODHD · analysis by claude-code · as of 6/21/2026, 8:48:20 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.